Skip to main content
Premium Trial:

Request an Annual Quote

Barry Polisky, Bruce Thaw, James Rothman, Steven Quay

Premium
MDRNA has appointed Barry Polisky as its CSO.
 
Polisky will replace Steven Quay, who will be stepping down from his roles as CSO and chairman of the company’s board of directors and scientific advisory board.
 
Previously, Polisky served as research vice president of Merck. He also served as CSO of Sirna Therapeutics prior to its acquisition by Merck. He holds a PhD in molecular biology from the University of Colorado.
 
MDRNA also announced that Bruce Thaw, lead independent director of the company, will assume the role of chairman of the board. James Rothman, a member of MDRNA’s scientific advisory board, has also been named chairman of the SAB.
 
In conjunction with the appointments, MDRNA said that former President, CEO, and Chairman Steven Quay will step down from the company. He will remain a member of both boards.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.